Clinical Trials Logo

Clinical Trial Summary

The objective is to determine the optimum dose of thrombolytic and duration of the ultrasound procedure (together defined as the APT Procedure) as a treatment for acute submassive pulmonary embolism (PE). Symptomatic submassive PE are participants with acute (less than or equal to [≤]14 days) PE with normal systemic arterial blood pressure (greater than [>] 90 mmHg) and evidence of RV dysfunction (right ventricular to left ventricular diameter ratio, that is; RV/LV ratio greater than or equal to [≥] 0.9). Participants with submassive PE will be randomized to one of four APT treatment groups: ultrasound of 2 and 6 hours (hrs) with r-tPA 2 milligrams (mg)/hr/catheter and ultrasound 4 and 6 hours with r-tPA, 1 mg/hr/catheter. On 08 June 2016, randomization into treatment group 4 (APT/6 hours-r-tPA/2 mg/hr/catheter) was closed following a reported intracranial hemorrhage (ICH) and death in a study participant in this arm.


Clinical Trial Description

This study is designed to investigate the lowest recombinant tissue plasminogen activator (r-tPA) dose-ultrasound treatment time required to achieve the same reductions in thrombus burden and associated improvement in physiologic parameters demonstrated in ULTIMA (EKOS 08 [NCT01166997]) and SEATTLE II (EKOS 09 [NCT01513759]). Results of this study are intended to inform the study design for further studies of the Acoustic Pulse Thrombolysis (APT) Procedure. Analysis of the first 100 evaluable participants in the United States study suggested a degree of equipoise between treatment groups 1, 2 and 3 of the protocol and therefore the sample size has been extended and additional sites in the United Kingdom (UK) National Health Service included, with a view to adding to the findings of the OPTALYSE study from sites in the UK and increasing the number of participants treated by treatment protocol. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02396758
Study type Interventional
Source Boston Scientific Corporation
Contact
Status Completed
Phase Phase 4
Start date June 12, 2015
Completion date January 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06348459 - Registry of Catheter Intervention in Pulmonary Embolism
Recruiting NCT03450304 - Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboembolic Pulmonary Hypertension: Comparative Study With Right Heart Catheterization and V/Q N/A
Not yet recruiting NCT06232551 - Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism N/A
Completed NCT03426124 - An International Pulmonary Embolism Registry Using EKOS
Not yet recruiting NCT06415968 - Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations
Recruiting NCT06051032 - Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy vs. Thromboaspiration. N/A
Recruiting NCT05098769 - A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
Enrolling by invitation NCT04855370 - Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE N/A
Recruiting NCT05482269 - Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography
Active, not recruiting NCT05481242 - An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients
Completed NCT04632641 - Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial N/A
Recruiting NCT03101384 - Influence of Diagnostic Errors on the Prognosis of Acute Pulmonary Embolism N/A
Completed NCT04374617 - Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19